PMID int64 27.8M 36.2M | Title/Abstract stringlengths 7 10.7k | MeshTerms stringlengths 7 104 | SemanticTypes stringlengths 4 84 |
|---|---|---|---|
34,666,493 | endotheli cell loss par plana vitrectomi analys chang endotheli cell densiti ecd par plana vitrectomi ppv identifi factor implic | D042783;D014821 | T025;T061 |
34,666,492 | oct angiographi diseas vitreoretin interfac present use optic coher tomographi angiographi octa vitreoretin interfac diseas result macular capillari network evalu idiopath macular hole surgeri imd | D019773;D012167 | T047;T020 |
34,666,491 | artefici intellig diabet retinopathi screen review aim comprehens paper acquaint reader evalu retin imag use artefici intellig ai main focus paper diabet retinophati dr screen basic principl artifici intellig algorithm alreadi use clinic practic short approv describ | D003920;D003930 | T047 |
34,666,488 | accur biomolecular structur nano lego approach pick brick build geometri determin accur equilibrium molecular structur play fundament role understand mani physic chemic properti molecul rang precis evalu electron structur analysi role play dynam environment effect tune overal behavior small semi rigid system gas phase state art quantum chemic comput rival sophist experiment exampl high resolut spectroscopi result larger molecul effect comput approach must devis end enlarg compil avail semi experiment se equilibrium structur cover import fragment contain h b c n f p cl atom collect new se databas next comparison geometri optim method root densiti function theori show alreadi remark result deliv pwb especi rev dsdpbep function improv linear regress lr approach use templat fragment taken se librari togeth lr estim miss interfrag paramet pave rout toward accur structur larg molecul wit small deviat comput experiment rotat constant whole approach implement user friend tool term nano lego appli number demand case studi | D011789 | T170 |
34,666,487 | drug repurpos identifi nilotinib potenti sar cov main proteas inhibitor insight comput vitro studi covid acut viral pneumonia emerg devast pandem drug repurpos allow research find differ indic fda approv investig drug current studi sequenc pharmacophor molecular model base screen covid pro pdb lu suggest subset drug drug bank databas may antivir activ total promis virtual hit drug bank subject molecular dynam simul experi explor strength interact sar cov pro activ site md find point toward three drug db db db low relat free energi sar cov pro interact met md simul identifi addit interact glu enhanc bind affin signific therefor glu could interest target structur base drug design quantit structur activ relationship analysi perform promis hit molecular dock base virtual screen partial least squar regress accur predict valu independ drug candid bind energi impress high accuraci final ec cc drug candid measur sar cov cell cultur nilotinib bemcentinib ec valu respect summari result comput aid drug design provid roadmap ration drug design pro inhibitor discoveri certifi medic covid antivir therapeut | D000086382;D011480 | T047;T121;T067 |
34,666,486 | nanopipett electrochem studi enhanc enzymat activ femtolit space chemic reaction confin space known acceler due high collis probabl howev studi confin effect supersmal space femtolit fl seldom report adjust volum picolit pl fl aqueous phase retrain tip nanopipett organ solvent confin effect specif activ glucos oxidas investig activ determin amount hydrogen peroxid generat reaction oxidas glucos use nanoelectrod insid nanopipett compar activ bulk solut umg activ increas umg fl space order magnitud increas enzymat activ highest amplif volum confin enzym reaction report near exponenti drop activ observ increas space volum reveal domin enhanc confin space fl level first time establish electrochem nanopipett provid strategi studi enzymat activ supersmal confin space also help understand confin effect enzym catalyz reaction | D005949;D006861 | T116;T121;T130;T197;T126 |
34,666,484 | ganoderterpen new triterpenoid ganoderma lucidum attenu lps induc inflamm apoptosi via suppress mapk tlr nf b pathway bv cell investig fruit bodi edibl mushroom ganoderma lucidum produc steroid contain one new lanostan type triterpen compound name ganoderterpen nuclear magnet reson high resolut electrospray ionize mass spectrometri data use deduc structur isol evalu abil suppress generat bv microgli cell treat lipopolysaccharid lps exhibit moder strong inhibit effect ic valu rang among test compound compound exhibit mark activ ic valu structur activ relationship studi studi show compound signific suppress activ mapk tlr nf b signal pathway evidenc immunofluoresc assay molecular dock experi furthermor compound effect improv lps induc mitochondri membran potenti apoptosi find suggest ganoderterpen could exert protect effect microgli cell apoptosi restrain inflammatori respons henc g lucidum could use novel prevent agent neurodegen disord | D032902;D020940;D014315 | T004;T109 |
34,666,482 | de novo synthesi elastin like polypeptid elp appli overview current experiment techniqu elastin like polypeptid elp protein base biopolym genet produc polypeptid compos repeat pentapeptid sequenc v p g x g inher properti recombin elp smart natur control sequenc complex physicochem properti biocompat make polym suitabl use nanobiotechnolog applic biofunction scaffold tissu engin purpos drug deliveri work report design synthesi two elastomer self assembl polypeptid elp mimic endogen human tropoelastin use molecular biolog techniqu two artifici gene encod two elp concatem approxim molecular mass kda one carri biotin bind peptid motif construct motif could facilit biofunction elp tether biotinyl factor growth factor elp heterolog overexpress e coli subsequ purifi two step nonchromatograph techniqu organ solvent extract follow nickel nitrilotriacet acid ni nta affin chromatographi character biochem properti biocompat elp also perform studi elp carri biotin bind motif test capabl bind biotin inde observ bind biotinyl protein specif addit result concern cytotox elp exhibit excel compat elp mammalian cell vitro anticip elp use compon scaffold mimic e xtra c ellular atrix ecm regener endogen high elast tissu | D004549;D004926 | T116;T007;T123 |
34,666,481 | pentafluorosulfanyl sf superior f magnet reson report group signal detect biolog activ teriflunomid deriv fluorin f magnet reson imag mri sever limit low signal nois ratio snr tap f drug detect vivo still pose signific challeng howev bear potenti label free theranost imag recent detect fluorin dihydroorot dehydrogenas dhodh inhibitor teriflunomid tf noninvas anim model multipl sclerosi ms use f mr spectroscopi mrs present studi probe distinct modif cf group tf improv snr reveal sf superior altern cf group valu sf bioisoster f mri report group within biolog pharmacolog context far underexplor compar biolog pharmacolog activ differ tf deriv f mr properti chemic shift relax time f mr snr effici three mri method reveal sf substitut tf highest f mr snr effici combin ultrashort echo time ute mri method chemic modif reduc pharmacolog biolog activ shown vitro dihydroorot dehydrogenas enzym cell prolifer assay instead sf substitut tf show improv capac inhibit cell prolifer indic better anti inflammatori activ suitabl viabl bioisoster context studi propos sf novel superior f mr report group ms drug teriflunomid | D003437;D000090722 | T116;T126;T109;T123 |
34,666,480 | interpret thought world report hear hear | D006309;D006310 | T039;T074 |
34,666,479 | research advanc chronic sinus children crscrscrscrs crscrscrscrscrs | D012852 | T047 |
34,666,478 | suscept factor progress diagnosi treatment difficult treat rhinosinus difficult treat rhinosinusitisdtrscrscrsdtrsdtrsdtr | D012220;D012852 | T047 |
34,666,477 | patient report outcom measur adult patient chronic rhinosinus ct | D012220;D012852 | T047 |
34,666,476 | diagnosi treatment extens osteonecrosi maxilla caus enterobact cloaca infect diabet case report | D003920;D010020 | T047;T046 |
34,666,475 | intraduct carcinoma parotid gland case report intraduct carcinomasidcidc bidc | D002285;D010307 | T191 |
34,666,474 | multipl giant cell repar granuloma craniofaci bone case report | D001859;D005870;D006101 | T191;T047;T046 |
34,666,473 | tonsillectomi treatment sapho syndrom case report synov acn pustulosi hyperostosi osteitissapho | D020083;D014068 | T047;T061 |
34,666,472 | explor cochlear implant frontometaphys dysplasia patient mapk gene mutat case report mapk cc tpplcategori auditori performancecap | D019929;D003054;D010009 | T047;T074;T019;T061 |
34,666,471 | analysi case emerg thyroid surgeri object investig clinic featur case emerg thyroid surgeri method nineteen case treat emerg thyroid surgeri may may analys retrospect includ male femal age year old among case nodular goitr case thyroid malign one case underw tracheal stent oper emerg thyroid surgeri due sever dyspnea case treatment outcom prognos patient evalu result patient underw general anesthesia endotrach intub one patient underw extracorpor membran oxygen ecmo two patient underw cardiopulmonari bypass six case nodular goitr underw proxim thyroidectomi eight case malign tumor underw total thyroidectomi six case invad trachea underw tracheal end end anastomosi partial tracheal resect one case underw tumor resect sternal sternum approach cervic mediastin lymph node dissect total laryngectomi tracheal low ostomi two case extens involv malign tumor given definit diagnosi tracheostomi three case malign lymphoma one underw total thyroidectomi two given definit diagnosi tracheostomi complic hemorrhag recurr laryng nerv parathyroid injuri occur oper patient follow month except case die due tumor progress rest aliv conclus patient obvious dyspnea caus thyroid tumor high mortal rate treat activ emerg surgeri reliev respiratori obstruct save live patient patient get radic cure well | D013964;D013965 | T191;T061 |
34,666,470 | applic valu intraop neuromonitor plus classif ebsln protect extern branch superior laryng nerv object investig applic efficaci classif extern branch superior laryng nerv ebsln combin intraop neuromonitor ionm dissect ebsln protect nerv injueri compar ligat branch superior thyroid vessel without attempt visual identifi nerv method prospect random control studi perform center patient subject thyroidectomi januari june random divid group patient experiment group underw thyroidectomi classif ebsln ionm dissect ebsln patient control group receiv synchron surgeri without attempt visual identifi nerv anatom subtyp ebsln experiment group record voic handicap index vhi score evalu movement bilater vocal cord examin laryngoscop surgeri month month month surgeri respect spss statist softwar use statist analysi result among ebsln patient male femal age year old ebsln experiment group ebsln control group total ebsln experiment group identifi ionm includ type type type b type type b type c statist signific differ baselin data group p patient follow month postop nerv injuri rate experiment group signific lower control group vs p vhi score laryngoscop result experiment group better control group three follow visit p postop laryngoscop examin patient experiment group patient control group show vocal cord relax bilater obliqu asymmetri phenomena consid result perman injuri patient symptom reliev vari degre follow symptom consid result temporari injuri conclus ionm combin classif ebsln reduc signific risk ebsln injuri thyroidectomi better direct ligat branch without attempt visual identifi nerv | D061224;D016343 | T060;T037 |
34,666,469 | combin autolog fascia transplant autolog fascia fat inject vocal fold sulcus vocali object assess voic outcom surgic techniqu type type sulcus vocali method data case bilater type sulcus vocali collect analyz retrospect patient bilater type sulcus vocali patient type one side typeon contralater vocal cord vocal cord appli autolog anterior rectus sheath fascia transplant side vocal cord type sulcus vocali also appli autolog fascia fat inject two male patient whose result transplant inject satisfi carri cricothyroid myotomi one year surgeri subject object voic evalu perform oper result one patient found mild adhes middl part vocal cord patient recov well complic week surgeri breathi voic feather vocal qualiti glottal closur gradual improv becam steadi month show subject object paramet except fundament frequenc signific improv p obvious improv achiev glottal closur mucos wave patient three patient obtain signific vocal qualiti improv transplant inject surgeri two male patient achiev improv mucos wave mpt bilater cricothyroid muscl amput one patient reveal mild adhes achiev satisfi result adhes separ sutur patient origin feel fatigu voic discontinu phonat gain signific improv postop steadi function complic observ month year patient follow period conclus autolog fascia transplant combin fascia fat injcet lead excel long term result good treatment option patholog sulcus vocali cricothyroid muscl amput reduc tension may improv vibrat properti vocal fold patient patholog sulcus vocali | D007821;D014827 | T023;T024 |
34,666,468 | differ concentr special pro resolv mediat eosinophil non eosinophil chronic rhinosinus nasal polyp object investig differ concentr special pro resolv mediat spms deriv fatti acid eosinophil chronic rhinosinus nasal polyp ecrswnp non eosinophil chronic rhinosinus nasal polyp necrswnp method total patient bilater chronic rhinosinus nasal polyp crswnp underw endoscop nasal surgeri peke union medic colleg hospit may septemb enrol includ male femal age year case ecrswnp case necrswnp time control subject enrol concentr multipl spms includ lipoxin lxa lxb resolvin rvd rvd rvd rvd rve protectin pdx maresin mar nasal polyp differ histolog subtyp normal nasal mucosa analyz use liquid chromatographi tandem mass spectrometri concentr spms group compar use mann whitney u test spearman rank correl coeffici use measur correl concentr spms nasal polyp tissu eosinophil count result concentr rvd rvd rvd lxa lxb mar pdx ecrswnp group signific higher control z valu respect p concentr rvd rvd mar pdx ecrswnp group signific higher necrswnp group z valu respect p concentr rvd rvd rvd lxb mar pdx nasal polyp correl posit tissu eosinophil count r valu respect p conclus varienti spms elev ecrswnp dysregul fatti acid metabol might play import role chronic inflamm ecrswnp | D009298;D012220;D012852 | T047 |
34,666,467 | gene transcriptom analysi nasal epitheli cell chronic rhinosinus nasal polyp object identifi differenti express gene nasal epitheli cell chronic rhinosinus nasal polyp crswnp analyz relat gene involv defici nasal epitheli barrier crswnp patient analyz dataset download gene express omnibus geo databas method mrna express microarray data number gse crswnp control gse crswnp control download public avail geo databas two dataset joint analyz screen differenti express gene nasal epitheli cell control crswnp patient meanwhil evalu function annot regulatori pathway differenti express gene confirm observ sinus tissu collect patient crswnp case year uncin process tissu collect patient nasal septum deviat case year control group primari epitheli cell nasal mucosa cultur mrna level screen gene measur q pcr spss softwar use statist analysi result gse dataset show differenti gene nasal epitheli cell crswnp control group differenti express gene gse dataset final regul gene regul gene notic nasal epitheli cell crswnp patient two dataset go gene function annot analysi show sptbn fnbpl vapb snx involv cell adhes function mapb particip format microtubul relat complex kegg pathway enrich analysi indic bambi siah involv regul wnt pathway cola eif involv regul pik akt pathway string protein interact network analysi assum mapb vapb core function protein among top differenti express gene cola mapb bambi mapb gene increas nasal epitheli cell crswnp patient comparison control conclus increas mapb gene epitheli cell crswnp well abnorm regul wnt pik akt signal pathway may mediat barrier dysfunct crswnp | D009298;D012220 | T047 |
34,666,466 | express signific trpm among chronic rhinosinus nasal polyp object compar express differ melastatin relat transient receptor potenti trpm among chronic rhinosinus nasal polyp normal mucosa tissu explor signific express trpm among crswnp method fifti one patient underw endoscop sinus surgeri depart otorhinolaryngolog head neck surgeri renmin hospit wuhan univers februari januari recruit includ male femal age year old immunohistochemistri use detect express trpm protein among crssnp crswnp control tissus addit correl express trpm protein crswnp patient preoper ct lund mackay score preoper vas score sinonas outcom test score analyz respect primari human nasal epitheli cell cultur vitro express trpm detect quantit real time pcr western blot tissu control group chronic rhinosinus without nasal polyp crssnp group crswnp group collect grind tissu homogen express trpm protein detect western blot h stimul homogen ad medium rpmi primari nasal epitheli cell result compar control express trpm signific regul nasal polyp p addit express trpm crswnp patient posit correl preoper ct lund mackay score vas score snot score r p r p r p cultur primari epitheli cell vitro express level trpm epitheli cell deriv nasal polyp signific higher control group p ad homogen control crssnp crswnp tissu express trpm rpmi cell primari nasal epitheli cell chang signific increas ad homogen group crswnp conclus trpm high express nasal polyp epitheli cell suggest trpm may involv pathogenesi nasal polyp regul nasal epitheli cell | D009298;D012220;D012852;D050053 | T116;T047;T123 |
34,666,465 | predict diagnost valu serum hydroxyvitamin eosinophil chronic rhinosinus nasal polyp object compar valu hydroxyvitamin oh clinic paramet predict diagnosi eosinophil chronic rhinosinus nasal polyp ecrswnp method elig chronic rhinosinus nasal polyp crswnp patient healthi subject affili hospit guizhou medic univers januari april includ studi age gender past histori basic characterist subject record crswnp patient classifi ecrswnp non eosinophil chronic rhinosinus nasal polyp necrswnp endotyp percentag tissu eosinophil serum oh level measur perform subject paranas sinus ct scan blood eosinophil count determin total immunoglobulin e total ige thth plasma cytokin nasal nitric oxid nno level perform surgeri logist regress analysi use evalu relat factor ecrswnp receiv oper characterist roc curv use evalu predict potenti clinic paramet result one hundr twenti seven crswnp patient healthi subject recruit includ male femal patient age year patient ecrswnp serum oh level signific lower necrswnp patient ngml vs ngml p preval asthma preval allerg rhiniti peripher blood eosinophil count total ige level nno level ct score ratio ethmoid sinus maxillari sinus em ratio ecrswnp patient signific higher necrswnp patient p among predict indic oh highest predict valu roc area curv auc valu best cut point ngml oh demonstr sensit specif ecrswnp conclus measur serum oh level may use effect method distinguish ecrswnp necrswnp | D009298;D012220;D012852 | T047 |
34,666,464 | concord system local eosinophilia relat poorer diseas control patient nasal polyp object explor whether blood polyp tissu eosinophil number independ risk factor poor diseas control patient nasal polyp method use electron medic record databas manual evalu nasal polyp patient undergon endoscop sinus surgeri least one year prior studi complet data tissu specimen baselin blood routin test nasal endoscopi sinus comput tomographi identifi recruit assess diseas control base criteria european posit paper rhinosinus nasal polyp epo multipl logist regress model use determin associ blood tissu eosinophil number risk poor diseas control adjust demograph comorbid result broke cohort group accord blood l tissu eosinophil patient without eosinophil inflamm repres largest group group concord blood tissu eosinophilia repres second largest patient isol tissu blood eosinophilia relat rare multipl logist regress model found blood eosinophil count tissu eosinophil percentag independ associ increas risk poor diseas control adjust covari relat poor treatment outcom furthermor subject concord blood tissu eosinophilia higher risk poor diseas control isol blood tissu eosinophilia conclus concord blood tissu eosinophilia relat higher likelihood poor diseas control isol blood tissu eosinophilia adjust potenti confound nasal polyp patient | D004802;D009298;D012220;D012852 | T047 |
34,666,463 | short term efficaci anti ige monoclon antibodi patient recurr chronic rhinosinus nasal polyp combin asthma object investig short term efficaci anti ige monoclon antibodi omalizumab treatment recurr chronic rhinosinus nasal polyp crswnp complic asthma method patient recurr crswnp comorbid asthma beij tongren hospit may decemb continu recruit receiv month therapi stabl background treatment plus omalizumab result visual analog scale vas nasal symptom sino nasal outcom test snot nasal polyp score collect baselin post treatment month treatment blood routin test total nasal resist tnr minimum cross section area mca total nasal caviti volum ncv forc expiratori volum one second fev forc vital capac fvc advers event collect baselin month treatment result evalu short term efficaci omalizumab graphpad prism use statist analysi result ten patient collect includ male femal age year old xs compar result baselin vas score nasal obstruct rhinorrhea hyposmia headach month treatment signific decreas vs vs vs vs valu respect p score snot vs p nasal polyp score vs p count percentag eosinophil peripher blood signific decreas l vs l vs valu respect p ncv cm cm patient improv baselin cm vs cm cm vs cm valu respect p conclus month treatment omalizumab signific improv nasal symptom qualiti life patient recurr crswnp complic asthma shrink nasal polyp size reduc number peripher blood eosinophil omalizumab use altern therapi refractori crswnp patient futur | D001249;D009298;D012220 | T047 |
34,666,461 | biolog new option treatment chronic rhinosinus nasal polyp crswnpcrswnpcrswnpcrswnp | D001688;D009298;D012220;D012852 | T047;T121;T123 |
34,666,460 | popular applic island shape design technolog local flap head neck | D058752;D006258;D019651 | T191;T024;T061 |
34,666,459 | research applic advanc imag techniqu cilia | D002923 | T026 |
34,666,458 | research progress excitatori inhibitori input later superior oliv | D065832 | T023 |
34,666,457 | stratifi strategi evalu dizzinessvertigo histori | D004244;D014717 | T033;T047;T184;T046 |
34,666,456 | vancomycin bone cement treatment radiat induc neck soft tissu necrosi sternal clavicular osteomyel laryng cancer surgeri case report mr | D007822;D010019 | T191;T047 |
34,666,455 | remov excess length superior cornu thyroid cartilag suspens laryngoscop case report ct | D029768;D003680;D007818;D019838 | T047;T002;T037 |
34,666,454 | primari giant laryng myofibroblastoma child case report inflammatori myofibroblast tumorimt ct cm cm cmimt | D007827;D009379 | T191;T047 |
34,666,453 | case tuberculosi diagnos tracheoesophag groov space occupi | D014138;D014376 | T190;T047 |
34,666,452 | carney complex character jugular foramen myxoma case report carneycarney | D056733;D000080869;D009232 | T191;T047;T030 |
34,666,451 | repair larg pharyng fistula multidisciplinari therapi advanc hypopharyng carcinoma case report tanmb cm cm | D002277;D005402;D007012;D010608 | T190;T191;T047 |
34,666,450 | metal strip penetr orbit neck thorax success remov multidisciplinari manag h ct | D009915;D014950 | T037;T030 |
34,666,449 | use coblat resect nasopharyng angiofibroma nasopharynx nasal endoscop report case ctmri | D018322;D009303 | T191 |
34,666,448 | correl differ bodi mass index anatom posit tongu arteri object compar anatom posit lingual arteri peopl differ bodi mass index bmi observ whether correl differ bodi mass index height weight tongu length tongu width bilater lingual arteri distanc lingual arteri depth estim posit lingual arteri oper guid oper method three hundr fourteen subject underw ct angiographi comput tomographi angiograph cta first affili hospit chongq medic univers june septemb random select retrospect analysi includ male femal peopl age year old subject divid group low bodi weight bmi kgm n normal bodi weight kgm bmi kgm n super weight group kgm bmi signific differ tongu length lingual arteri depth measur point p pearson correl analysi show bmi signific posit correl bilater lingual arteri distanc measur point r p bmi signific posit correl tongu length r p tongu width conclus patient differ bmi valu locat lingual arteri differ posit correl individu surgic plan made accord patient differ bmi valu tongu bodi surgeri avoid damag lingual arteri | D020181 | T047 |
34,666,447 | clinic diagnosi treatment type congenit laryngotracheoesophag cleft children object investig clinic diagnosi treatment congenit laryngotracheoesophag cleft ltec children method clinic data children includ male femal congenit laryngotracheoesophag cleft januari june retrospect analyz median diagnos age month day month accord modifi benjamin ing classif propos sandu case type case type case type b case type children follow regular result six patient treat recurr bronchopneumonia aspir feed patient first treat pneumolog departmentt intens care unit six patient combin malform endoscop repair oper perform case case type case type case ltec oper cervic approach case type iva ltec associ vacterl repair thoracoscop combin suspens laryngoscop seven patient underw tracheotomi repair oper gastrostomi perform children oper success perform case three children type ltec recov well decannul one case type follow month occasion choke feed two case type case type b case type die due sever reflux tracheomalacia respiratori failur conclus congenit ltec rare congenit malform difficult diagnos poor specif clinic manifest ltec need classifi endoscopi examin general anesthesia sever case ltec poorer outcom mild case periop manag need multi disciplinari cooper reduc mortal | D007830;D014132 | T023;T030 |
34,666,446 | identif genet analysi new mutat eya gene bos syndrom object analyz clinic manifest patient branchioot syndrom bos famili carri genet test order specifi biolog pathogenesi method clinic data patient famili collect genom dna peripher blood proband famili member extract exon deaf relat suscept gene well flank region sequenc high throughput sequenc mutat site proband parent valid sanger sequenc result nine member three generat four present hear loss preauricular fistula branchial fistula met diagnost criteria bos proband mother present auricl malform inner ear malform one abnorm kidney patient pedigre analysi reveal mode inherit famili consist autosom domin pattern mutat analysi show affect patient detect heterozyg frameshift variat cdelt eya gene report genotyp phenotyp co isol famili frameshift variat produc prematur termin codon therebi caus prematur termin translat pcvfs acmg identifi mutat pathogen mutat novel detect control heterozyg missens variat mutat cg pgs eya gene also detect three member famili acmg identifi mutat clinic signific uncertain howev two normal seem diseas caus mutat famili conclus novel frameshift mutat eya cdelt main molecular etiolog bos chines famili studi expand mutat spectrum eya gene clinic manifest heterogen among patient famili diagnosi bos combin gene test clinic phenotyp analysi | D019280 | T047 |
34,666,445 | clinic imag featur middl ear hairi polyp object collect clinic case middl ear hairi polyp summar imag featur method retrospect analyz clinic data four case middl ear hairi polyp confirm surgic patholog januari januari affili eye ent hospit fudan univers three femal one male two left ear two right ear age year ct mri imag patient correspond clinic manifest analyz result hairi polyp origin tympanum one case origin eustachian tube two case exhibit recurr otorrhea without evid induc case hairi polyp origin eustachian tube pharyng orific protrud nasopharyng caviti pharynx discomfort aural full endoscop show offwhit polypoid mass littl hair four case present polypoid soft tissu mass ct mri imag contain soft tissu wall larg amount adipos tissu soft tissu center mass like core enhanc mri show stratifi arrang fat soft tissu wall mass four case surgic treatment postop patholog examin present hair follicl matur sebac gland skin appendag found squamous epithelium larg amount adipos tissu part muscl tissu cartilag tissu fibro collagen tissu prolifer mass accompani collagen degener conclus middl ear hairi polyp imag characterist polypoid soft tissu mass usual look smooth contain larg amount adipos tissu soft tissu center suggest diagnos ct mri | D004427;D005064;D011127 | T190;T023;T047 |
34,666,444 | retrospect studi thyroid invas central lymph node metastasi patient hypopharyng carcinoma object investig characterist thyroid invas central lymph node metastasi hypopharyng carcinoma impact surviv rate qualiti life method retrospect analysi case male femal age rang year old laryngopharyng squamous cell carcinoma initi treat depart head neck surgeri beij tongren hospit affili capit medic univers januari decemb perform clinic data includ tumor locat patholog stage patholog n stage invas thyroid gland central lymph node metastasi surgic procedur patient group accord presenc thyroid invas central lymph node metastasi follow surviv analyz kaplan meier method tumor recurr metastasi evalu result patient patient thyroid involv patient central lymph node metastasi incid thyroid involv pyriform sinus posterior pharyng wall posterior cricoid wall statist signific differ p incid central lymph node metastasi pyriform sinus posterior pharyng wall posterior cricoid wall also statist signific differ p statist correl thyroid invas central lymph node metastasi gender smoke alcohol exposur histori tumor patholog differenti p year overal surviv rate year recurr free rate total patient die year includ case thyroid invas group case central lymph node metastasi group local recurr occur patient includ case thyroid invas group case central lymph node metastasi group signific differ surviv patient without thyroid invas central lymph node metastasi p signific differ year overal surviv relaps free surviv among group differ stage n stage patholog stage tumor patholog differenti level p signific differ level serum calcium ft group without thyroid invas central lymph node metastasi p conclus incid thyroid invas central lymph node metastasi hypopharyng carcinoma rare risk occurr relat primari site tumor comprehens evalu correct decis make accur treatment could help cure radic tumor prevent recurr improv qualiti life patient | D002294;D006258;D013964 | T191 |
34,666,443 | effect analysi endoscop transnas resect epidur cholesteatoma paracentr skull base object indic clinic featur endoscop transnas resect epidur cholesteatoma paracentr skull base analyz efficaci method total excis rate postop complic postop curat effect patient male femal age year old underw middl skull base surgeri epidur cholesteatoma resect transnas endoscop tianjin huanhu hospit august august retrospect review patient follow month postop mri clinic symptom recurr review descript statist method use analysi result among patient total resect complet resect cyst content capsul patient near total resect complet resect cyst content incomplet resect cyst capsul patient subtot resect incomplet resect cyst content capsul patient clinic symptom patient improv postop patient clinic symptom one case postop cerebrospin fluid rhinorrhea cure lumbar drainag nasal iodoform gaug pack patient includ patient partial resect recurr conclus endoscop transnas approach may effect use resect epidur cholesteatoma paracentr skull base care select case | D002781;D009364 | T191;T047 |
34,666,442 | studi featur cortic auditori evok potenti differ auditori task cochlear implant children object investig variat regular influenc factor cortic auditori evok potenti caep evok pure tone syllabl tone stimuli cochlear implant ci children method cortic auditori evok potenti caep respons collect ci children sound field pure tone frequenc khz khz use standard deviant respect pure tone stimul condit chines mandarin tokensba paandba bapair use stimuli respect syllabl tone stimul condit latenc amplitud presenc rate p mismatch negat mmn obtain correl difficulti auditori task age hear month durat sever profound hear loss wear histori hear aid ci hear threshold better ear ci latenc amplitud p mmn analyz statist analys figur conduct use spss result p presenc rate pure tone syllabl tone group respect signific differ p signific differ pure tone group tone group p signific differ pure tone group syllabl group syllabl group tone group mmn presenc rate pure tone syllabl tone group respect signific differ among three group differ auditori task p signific differ observ among three group differ auditori task latenc amplitud p mmn multipl linear regress analysi show latenc p posit correl difficulti auditori task hear threshold better ear ci negat correl hear age histori hear aid ci latenc mmn posit correl difficulti auditori task negat correl hear age conclus p presenc rate pure tone auditori task signific higher tone auditori task difficulti auditori task hear age histori hear aid ci hear threshold better ear ci signific effect p latenc difficulti auditori task hear age signific effect mmn latenc | D019929;D003054;D006310 | T074;T061 |
34,666,441 | evalu adhes bone conduct hear aid pediatr patient unilater congenit aural atresia object evalu auditori efficaci subject satisfact adhes bone conduct hear aid children unilater congenit aural atresia ucaa method ten subject male femal diagnos ucaa averag age year old rang includ beij tongren hospit capit medic univers januari august free sound field hear threshold word recognit score quiet speech recept threshold nois sound local abil result measur rms error test perform unaid aid situat respect subject satisfact questionnair also distribut subject pair test wilcoxon sign rank test use statist analysi method result averag hear threshold aid condit improv db p speech recognit abil general improv quiet nois p effect improv aid condit p subject got high satisfact rate three subject questionnair conclus adhes bone conduct hear aid provid signific audiolog benefit children ucaa well rais qualiti life | D006310;D013067 | T074;T041 |
34,666,440 | assess qualiti life mandibular ameloblastoma patient reconstruct doubl barrel fibula flap object analys qualiti life patient receiv repair bone defect fold fibula flap remov mandibular ameloblastoma method case data patient ameloblastoma admit first affili hospit zhengzhou univers august april retrospect analys includ male femal year old print digit technolog use flap prepar surgeri patient fold fibular flap use repair mandibular defect implant place month surgeri short form health survey questionnair sf univers washington qualiti life questionnair uw qol appli evalu qualiti life patient surgeri month month surgeri higher score better condit spss adopt statist analysi result sf survey show mean score bodi role surgeri signific higher month surgeri p month surgeri p compar preoper mean score physic pain general health health chang surgeri mean score physic pain general health health chang month surgeri decreas signific respect respect p mean score physic pain general health health chang month surgeri increas signific respect respect p signific differ mean score physic pain general health health chang month surgeri respect p uw qol survey show mean score chew languag tast function decreas month surgeri respect improv month surgeri respect statist signific differ respect p conclus applic fold fibula flap repair bone defect sugeri mandibular ameloblastoma better meet need languag chew function improv qualiti life patient | D000564;D058752;D008339;D019651 | T191;T024;T061 |
34,666,439 | clinic applic supraclavicular fasciocutan island flap repair tracheal defect object explor clinic applic supraclavicular fasciocutan island flap sif repair tracheal defect method may march clinic data patient male femal age year old retrospect analyz underw repair surgeri sif trachea defect resect cervic thorac tumor includ case laryngotrach adenoid cystic carcinoma case laryng carcinoma case esophag carcinoma case thyroid carcinoma one case parathyroid carcinoma primari tumor outcom case tracheal defect repair sif evalu result area sif cm cm thick flap mm length pedicl cm blood suppli sif came transvers carotid arteri skin defect donor area shoulder direct close month follow flap surviv flap trachea well shoulder wound heal well conclus sif suitabl repair tracheal defect perfect thick compat trachea techniqu simpl microsurg techniqu need good applic prospect | D019651;D014132 | T023;T061 |
34,666,438 | evalu shoulder function repair head neck defect supraclavicular flap object evalu shoulder function patient repair head neck defect supraclavicular flap method retrospect analysi perform patient male femal age year old receiv repair head neck defect supraclavicular flap depart otorhinolaryngolog head neck surgeri beij tongren hospit capit medic univers januari decemb area type flap disrupt infect incis donor site postop complic record quick disabl arm shoulder hand quick dash use evalu shoulder function patient conform standard evalu clinic function shoulder upper limb compar postop upper limb function patient treat clavicular flap patient acromion flap meanwhil patient receiv bilater neck lymph node dissect period time select compar evalu donor side observ group opposit side control group data process spss result area obtain supraclavicular flap cm cm three patient show defect width cm donor site could nt sutur direct receiv repair shoulder defect partial flap defect patient sutur direct surgeri patient suffer disrupt acromion incis heal week local dress follow time month patient express dissatisfact appear among patient clavicular type acromion type acromion type show averag motor abil quick dash score higher clavicular type averag motor abil vs p quick dash vs p among patient receiv bilater neck lymph node dissect period time observ group show higher averag motor abil local symptom quick dash score control group averag motor abil vs p averag local symptom vs p quick dash vs p conclus shoulder dysfunct exist treatment supraclavicular flap relat flap type | D019651;D017695 | T037;T061 |
34,666,437 | clinic applic thoracodors arteri perfor flap repair head neck defect object analys clinic applic thoracodors arteri perfor flap tdapf repair head neck defect method retrospect review conduct patient oral maxillofaci head neck malign tumor underw radic resect oral oropharyng carcinoma tdapf repair depart oral maxillofaci head neck oncolog ninth peopl hospit affili shanghai jiao tong univers school medicin june novemb among male femal age year flap size vessel pedicl length diamet number perfor flap fat thick record count elasti meter skin fibro meter appli measur skin elast hard donor area kind skin flap flap prepar spss statist softwar use statist analysi data result flap surviv mean elast tdapf nm signific lower anterolater thigh nm p anterolater thigh nm p forearm flap nm p hard tdapf n also signific lower anterolater femor n f p anteromedi femor n f p forearm flap n f p follow period rang month patient treat tdapf good recoveri function recipi area scar donor area obvious surgeri without serious complic conclus tdapf suitabl reconstruct head neck defect ductil textur good recoveri morpholog function head neck | D061525;D019651 | T023;T061 |
34,666,436 | free rectus abdomini myocutan flap reconstruct major complex defect craniofaci region ablat advanc sinonas carcinoma object explor method plausibl use free rectus abdomini flap fraf reconstruct major complex defect craniofaci region ablat advanc sinonas carcinoma method hospit joint logist support forc peopl liber armi china patient advanc carcinoma nasal caviti paranas sinus includ male femal age year treat fraf repair invas skull base face orbit base adequ meticul preoper evalu patient tumor complet resect tumor bulk perform accord site charact extent defect fraf introduc differ way reconstruct major complex defect craniofaci region resect advanc sinonas carcinoma restor structur contour craniofaci region result complet resect tumor achiev case repair major complex defect result tumor ablat fraf graft conduct patient advanc sinonas carcinoma recipi vessel facial arteri vein case superfici tempor arteri vein case vascular bridg extern jugular vein carri case underw submandibular neck dissect facial arteri vein use recipi vessel free fibular flap use along fraf case undergon bilater maxillectomi pedicl galea capiti periost flap appli simultan case dura defect skullbas result tumor resect flap use case surviv unev without major complic success repair defect reconstruct structur restor contour craniofaci region conclus adequ evalu resect tumor well natur extent defect tumor remov fraf transplant ideal method strategi choic reconstruct major complex defect craniofaci region result tumor ablat advanc sinonas carcinoma | D002277;D064827;D019651 | T191;T024;T061 |
34,666,435 | arriv new era function repair head neck surgeri | D006258;D009333 | T191;T029 |
34,666,434 | effect respons coronavirus diseas pandem treatment outcom patient lymphoma multipl myeloma relat littl data avail respons coronavirus diseas covid pandem affect treatment outcom patient receiv chemotherapi lymphoma multipl myeloma aim determin effect covid countermeasur treatment outcom patient popul | D000086382;D008223;D009101 | T191;T047;T067 |
34,666,433 | nicotin exacerb tacrolimus induc renal injuri program cell death cigarett smoke import modifi risk factor kidney diseas progress howev under mechan lack studi aim assess whether nicotin nic major toxic compon cigarett smoke would exacerb tacrolimus tac induc renal injuri | D009538;D016559 | T131;T121;T109 |
34,666,432 | aerosol antibiot treatment hospit acquir pneumoniaventil associ pneumonia aerosol antibiot increas use treat respiratori infect especi caus drug resist pathogen use treatment hospit acquir pneumonia ventil associ pneumonia critic ill patient especi signific also use effici altern overcom issu caus system administr antibiot includ occurr drug resist strain drug toxic insuffici drug concentr target site howev rational use aerosol antibiot limit owe insuffici efficaci potenti underestim risk develop side effect despit lack avail high qualiti evid use aerosol antibiot consid attract altern treatment approach especi patient multidrug resist pathogen review discuss effect side effect aerosol antibiot well latest advanc field usag republ korea | D053717;D012141 | T047 |
34,666,425 | comparison prevail insulin regimen differ time period hospit patient real world experi tertiari hospit prevail insulin regimen glycem control hospit patient chang time aim determin whether current basal bolus insulin bbi regimen superior previous insulin regimen main compris split mix insulin therapi | D003924;D007003 | T047 |
34,666,420 | evolut low antibiot concentr risk select pseudomona aeruginosa multidrug resist mutant natur antibiot pollut non clinic environ might relev impact human health resist pathogen select howev potenti risk often overlook sinc drug concentr natur usual minim inhibitori concentr mic albeit antibiot resist bacteria select even sub mic concentr rang known sub mic select window use short term evolut experi determin sub mic select window opportunist pathogen pseudomona aeruginosa seven antibiot clinic relev find one quinolon widest one polymyxin b imipenem narrowest clinic relev multidrug resist mutant aros within sub mic select window antibiot test phenotyp mediat efflux pump activ fact concentr antibiot report aquat ecosystem coloniz p aeruginosa occas higher one select multidrug resist mutant assay implic understand role differ ecosystem condit emerg antibiot resist one health perspect reinforc import procur accur inform sub mic select window drug clinic valu pathogen environment nich | D000900;D011550 | T195;T007;T121 |
34,666,419 | random clinic trial effect exercis muscl remodel follow bariatr surgeri muscl atrophi strength loss common advers outcom follow bariatr surgeri random control trial investig effect exercis train bariatr surgeri induc loss muscl mass function addit investig effect intervent molecular histolog mediat muscl remodel | D050110;D015390;D009767 | T047;T061 |
34,666,418 | distinct represent ipsilater hand movement sensorimotor area ampl evid contralater sensorimotor area play import role movement generat primari motor cortex primari somatosensori cortex show detail spatial organ represent contralater bodi part interest also indic role motor cortex control ipsilater side bodi howev precis function ipsilater sensorimotor cortex unilater movement control still unclear show hand movement represent ipsilater sensorimotor hand area hand gestur distinguish contralater hand gestur high field function magnet reson imag fmri data acquir execut six left six right hand gestur healthi volunt show ipsilater activ main anterior section precentr gyrus posterior section postcentr gyrus despit lower activ ipsilater area closer central sulcus activ pattern hand gestur could mutual distinguish area exist uniqu represent ipsilater hand movement human sensorimotor cortex favour notion transcallos integr process support optim coordin hand movement | D009044;D066191 | T023;T029 |
34,666,417 | parent intervent peopl schizophrenia relat serious mental ill around third peopl schizophrenia relat serious mental ill parent parent children popul increas risk advers outcom due parent mental ill parent intervent known improv parent skill decreas child disrupt behaviour systemat review aim synthesis evid base parent intervent design specif parent schizophrenia relat serious mental ill | D001523;D012559 | T048 |
34,666,415 | predict distanc run perform femal runner use nomogram studi examin valid precis accuraci predict distanc run perform femal runner three nomogram offici rank french women track run event examin femal runner perform three distanc event within year includ n perform distanc predict use three nomogram two perform perform min smin min smin min smin respect differ found actual predict run perform regardless nomogram p predict run perform signific correl actual one high correl coeffici p bias limit agreement accept whatev nomogram less equal studi confirm valid three nomogram predict track run perform high level accuraci predict nomogram similar may use train program competit | D049451;D012420 | T170;T056;T081 |
34,666,414 | compensatori chang ground reaction forc small larg breed dog unilater hindlimb lame comparison healthi dog aim studi investig whether small medium size dog natur occur unilater hindlimb lame show compensatori chang ground reaction forc larg breed dog chang display compar healthi small medium size dog | D004283;D007794 | T047;T184 |
34,666,413 | evalu menisc load load distribut canin stifl tibial plateau level osteotomi postop tibia plateau angl degre aim studi investig kinet kinemat chang stifl tibial plateau level osteotomi tplo postop tibia plateau angl tpa either degre | D000070598;D004283;D000072600 | T023;T047;T037 |
34,666,412 | effect capsiat supplement maxim voluntari contract healthi men studi aim investig effect acut capsaicin analog capsiat cap supplement maxim voluntari isometr contract mvic perform healthi young men thirteen subject yrs particip present studi two differ day separ one week subject ingest capsiat mg placebo starch mg minut mvic test mvic test consist five second knee extens maxim isometr contract second recoveri effort peak forc mean forc minimum forc fatigu index area curv contract calcul main condit effect found higher valu peak forc f p fatigu index f p area curv f p cap compar placebo howev interact effect found variabl f p summari healthi young men produc higher maxim isometr forc delay fatigu cap condit compar placebo condit condit effect without signific differ effort | D002211;D018482 | T024;T023;T121;T109 |
34,666,411 | epidemiolog injuri olymp sport injuri effect perform athlet sever injuri determin time loss sport perform reduct treat injuri adequ necessari get overview vari injuri type differ sport disciplin retrospect studi athlet germani switzerland austria compet competit recreat level sport includ injuri preval highest team sport follow combat racquet track field knee shoulder risk joint time loss sport activ injuri longest region knee week report injuri accompani reduc level perform highest injuri preval occur year injuri occur train compar competit across olymp disciplin larg number injuri occur train session injuri frequenc increas olymp game drew closer knee shoulder injuri sever injuri respect time loss reduct sport perform | D001265;D000070599;D014142 | T056;T073;T037 |
34,666,410 | generaliz homeopath prognost factor research outcom covid treatment comparison data coronavirus diseas covid pandem sever homeopath prognost factor research pfr project undertaken found two project compar outcom assess consist possibl flaw | D000086382;D006705 | T047;T061;T067 |
34,666,409 | homeopathi covid prevent report intervent brazilian servic sector compani covid quick becam serious public health problem worldwid serious econom social repercuss homeopath around world studi find genus epidemicus ge medicin might help prevent treatment diseas | D000086382;D006705;D008419 | T047;T121;T061;T067 |
34,666,405 | delay complic follow dermal filler tear trough augment systemat review tear trough deform popular target treatment filler inject side effect general mild transient howev delay complic may occur aim perform thorough systemat review publish literatur relat delay complic tear trough filler inject search publish literatur conduct accord prefer report item systemat review meta analys prisma guidelin june includ pubm sciencedirect embas databas medic subject head mesh term use includ follow term delay complic nodul granuloma swell discolor dermal filler hyaluron acid ha polyacrylamid calcium hydroxyapatit caha poli l lactic acid plla eyelid periorbit periocular tear trough twenti eight articl consist individu case includ final analysi patient femal averag age year ha report product follow plla caha common delay complic dermal filler swell follow lump nodul xanthelasma like reaction migrat discolor also occur averag time onset complic month xanthelasma like reaction appear soonest mean month discolor appear latest mean month swell case caus ha semi perman filler pmma synthet filler plla like associ lump nodul complic import clinician perform tear trough augment dermal filler thorough understand risk procedur diagnos manag prompt well provid patient accur inform regard potenti advers effect | D003357;D000067548 | T122;T061 |
34,666,404 | comparison sodium lactat infus carbon dioxid inhal panic provoc test meta analysi sodium lactat nal infus carbon dioxid co inhal proven provok acut panic attack pas patient panic disord pd systemat literatur search meta analysi perform compar effect size method | D002245;D016584 | T048;T197;T123 |
34,666,403 | glecaprevirpibrentasvir sofosbuvir ribavirin salvag regimen sofosbuvir velpatasvir voxilaprevir treatment failur antivir therapi chronic hepat c virus hcv achiev sustain virolog respons svr major patient even initi virolog failur treatment combin sofosbuvirvelpatasvirvoxilaprevir sofvelvox establish effect second line regimen howev patient fail achiev svr second antivir cours sofvelvox patient consid difficult cure current optim regimen antivir treamtent matter debat european american guidelin suggest combin sofglecaprevirpibrentasvir gp ribavirin salvag regimen howev littl evid support studi data two patient genotyp chronic hcv infect liver cirrhosi virolog failur treatment sofvelvox success achiev svr combin sofgp rbv import one patient child b cirrhosi time treatment initi advers event report thus data support use sof gp rbv salvag regimen treatment failur sofvelvox | D019698;D000069474 | T047;T121;T114;T109 |
34,666,402 | corona ssc sever covid diseas secondari scleros cholang ssc sever complic intens care treatment critic ill patient character rapid onset sever chlolestasi elev ggt contrast primari scleros cholang ssc cip distinct time well defin trigger rapid progress cirrhosi liver failur context covid pandem report patient develop ssc sever covid infect intens care treatmentw report year old patient without relev pre exist ill suffer sever covid pneumonia need long term ventil cours diseas develop critic ill polyneuropathi pronounc cholestasi recoveri covid pneumonia pnp regress cholestasi progress mrcp show irregular intrahepat bile duct eus show echogen intraduct longitudin structur characterist intraduct cast ssc cip confirm erc complet necrot bile duct could extract retriev histolog molecular analysisth patient includ schedul erc program prevent progress ssc concomit cirrhosisssc often miss diagnosi obvious also occur covid patient case elev liver function test cholestasi eus might key diagnost method character intraduct cast identifi patient undergo erc | D000086382;D015209 | T047;T067 |
34,666,399 | gastric cancer incid mortal trend three european countri background increas awar gastric cancer risk easi access upper endoscopi high definit endoscop virtual chromoendoscopi may led increas earli diagnosi gastric cancer observ recent year europ may associ improv surviv current data exist impact earli diagnosi surviv popul level europ aim assess gastric cancer incid earli diagnosi surviv northwestern southern european countri low moder incid gastric cancer method data gastric cancer diagnos retriev nation cancer registri belgium netherland northern portug age standard incid mortal rate assess express per person year earli diagnosi defin tumor net surviv estim vs compar result age standard incid mortal decreas time belgium northern portug netherland relat incid decreas respect relat mortal decreas respect earli gastric cancer diagnosi increas time countri net year surviv improv signific two time period countri year belgium portug conclus first studi compar trend gastric cancer incid mortal european countri found increas proport gastric cancer decreas age standard mortal time support use secondari prevent strategi | D013274 | T191 |
34,666,393 | select toxic effect fatti acid omega combin glioblastoma neuron mitochondria glioblastoma gbm one common malign tumor central nervous system occur brain dead diseas despit differ approach treatment malign discoveri new compound anti cancer effect seem necessari studi select toxic effect omega combin mitochondria isol umg human glioma cell also human embryon kidney cell hek normal control investig result indic omega combin signific reduc succin dehydrogenas sdh activ mitochondria isol umg human glioma cell addit exposur mitochondria isol umg human glioma cell combin associ select increas level reactiv oxygen speci ros collaps mitochondri membran potenti mmp mitochondri swell cytochrom c releas howev effect observ mitochondria isol hek cell normal group accord result propos combin omega could induc toxic umg human glioma cell mitochondria combin help complementari therapi patient gbm | D005909 | T191 |
34,666,392 | deliveri ursol acid polyhydroxybutyr nanoparticl cancer therapi silico vitro studi ursol acid ua pentacycl triterpenoid phytochem potent inhibitori agent prolifer various tumor polyhydroxybutyr nanoparticl phb nps prefer therapeut due drug stabil properti enhanc biolog activ studi phb nps util deliv enhanc bioavail ua cancer cell hela molecular dock dynam studi conduct calcul bind affin stabil ua activ site target protein epiderm growth factor receptor egfr phb nps reveal averag size nm tem use subsequ experi cytoplasm uptak nanoparticl confirm floresc microscopi encapsul potenti phb nps ua assess uv visibl spectrophotomet besid drug releas behavior cytotox regul apoptosi investig vitro cytotox result reveal maximum effici drug deliveri th hour | D053758;D009369;D014315 | T191;T073;T109 |
34,666,391 | neuromyel optica spectrum disord present insight recent develop achiev last year essenti shape diagnost method therapi neuromyel optica spectrum disord nmosd discoveri aquaporin antibodi develop diagnost criteria path led approv eculizumab satralizumab first diseas modifi treatment europ articl give overview present insight futur treatment option | D009471 | T047 |
34,666,385 | effect covid pandem well babi nurseri coronavirus diseas covid pandem associ fewer deliveri prematur birth howev impact pandem well babi nurseri wbn unknown | D000086382;D047928 | T046;T047;T067 |
34,666,378 | counter covid vaccin hesit pregnanc cs despit evid support safeti efficaci covid vaccin pregnanc clear recommend profession organ center diseas control prevent cdc pregnant peopl get vaccin covid vaccin hesit pregnanc remain signific public health problem emerg high transmiss b delta variant among primarili unvaccin peopl expos cost vaccin hesit commentari explor factor contribut covid vaccin hesit pregnanc potenti solut overcom key point low covid vaccin coverag pregnant peopl major public health problem unit state covid vaccin hesit pregnanc multifactori cs framework may use counter covid vaccin hesit | D000086382;D011251 | T047;T067 |
34,666,370 | multipl congenit ocular anomali silver coat missouri fox trotter stallion first descript multipl congenit ocular anomali mcoa silver coat missouri fox trotter determin heterozyg silver pmel missens mutat associ mcoa silver coat breed stallion treat meningoenceph bilater uveiti unknown origin complet ophthalm examin ocular ultrasonographi perform incident find patient exhibit bilater cystic lesion restrict tempor anterior uvea consist cyst phenotyp genotyp heterozyg silver mutat addit non silver color missouri fox trotter genotyp homozyg wild type allel screen pmel mutat missouri fox trotter accompani ophthalm phenotyp character recommend determin allel frequenc facilit inform breed decis sinc silver coat color particular popular | D020125 | T045 |
34,666,369 | flock status sheep flock assess ressourc manag relat welfar indic welfar status sheep flock may assess via anim resourc manag relat indic benefit multipl choic questionnair howev impair divers sheep breed husbandri veterinari flock health manag point view present review describ influenc environ climat supervis well addit factor consider legal regul improv welfar common concern player field farm anim husbandri base challeng well possibl improv exist legal administr institut well pharmaceut industri | D000822;D012757 | T047;T090 |
34,666,368 | chronic bee paralysi virus quo vadi incid bavaria consider therapeut measur chronic bee paralysi virus cbpv far unclassifi rna virus may caus neurolog sign hairless black syndrom honey bee becom increas preval various european countri recent year diseas occasion lead immens loss worker bee signific drop perform especi strong coloni aim retrospect studi analys spread cbpv bavaria well evalu therapeut measur | D012328 | T005 |
34,666,367 | evalu clinic examin paramet score system equin colic well assess prognost valu hors colic associ relat high mortal rate identif paramet associ poor outcom may aid provid accur prognosi studi aim assess earli prognost valu toward surviv hors base paramet clinic examin | D003085;D006734 | T033;T047;T184 |
34,666,366 | option limit protect hors husbandri time grow wolf popul germani review literatur hors owner questionnair risk assess sinc wolf popul reestablish germani consequ increas number livestock damag caus wolv rise hors likewis affect aim studi provid overview challeng possibl solut | D006734;D019596 | T015;T047 |
34,666,365 | acut complex endovascular aortic repair shelf vs surgeon modifi stent graft treatment complex abdomin thoracoabdomin aortic aneurysm challeng open surgic repair high risk oper especi emerg case endovascular aneurysm repair patient specif custom made stent graft patient symptomat ruptur complex aortic aneurysm possibl due manufactur time requir case altern endovascular techniqu use | D017544;D017545;D019917;D057510;D066231 | T097;T047;T061 |
34,666,364 | aortic complic relat mycobacterium bovi intraves bacill calmett gurin therapi systemat review aortic complic intraves bacillus calmett gurin bcg applic rare complic treatment non muscl invas bladder cancer aim systemat review perform descript analysi previous publish studi discuss particular challeng diagnosi treatment rare complic | D000785;D009163;D001749 | T191;T007;T047 |
34,666,363 | prophylaxi type endoleak relev long term success evar one patient need reintervent evar first year two third secondari intervent aim treat endoleak preval complic doubl presenc endoleak fourth generat stent graft lead decreas type associ reintervent better prevent type endoleak pretreat potenti type feed arteri embolis agent treatment occurr type endoleak | D017544;D019917;D057510 | T047;T061 |
34,666,362 | ascend aorta aortic arch endovascular therapi today futur patholog region aortic arch may occur isol adjac segment thorac aorta ascend descend aorta much common affect first surgic procedur treat aortic arch perform near six decad ago despit numer improv innov th earli st centuri procedur still associ relev oper mortal neurolog complic rate endovascular techniqu modern hybrid procedur increas expand therapeut spectrum aortic arch although open surgic approach current still gold standard endovascular treatment aortic aneurysm first perform earli infraren abdomin aorta long first attempt endovascular therapi made treatment aortic arch inou et al report use first common use endoprosthesi treat aneurysm aortic arch continu improv refin implant techniqu also implant materi result endovascular therapi increas import option compar open surgic procedur descend thorac abdomin aorta partial replac gold standard review articl aim provid overview prerequisit result also limit endovascular surgeri aortic arch | D017545;D019917;D057510 | T047;T061 |
34,666,361 | pro endo need open surveil import sinc first report endovascular aneurysm repair evar becom establish prefer treatment modal mani patient sever randomis control trial compar evar open repair shown earli surviv benefit lower periop morbid shorter hospit stay evar result evar becom common method elect repair baa vascular centr despit widespread use still subgroup patient popul benefit evar clear demonstr frequent discuss subgroup context patient risk factor due concern durabl need reintervent evar provid durabl long term surviv similar open repair younger patient long aneurysm anatomi instruct use follow evid effect follow patient surviv current controversi increas knowledg behavior endoprosthes factor influenc complic endograft chang follow protocol made patient specif follow strategi less complianc rigor follow scheme requir | D017544;D019917;D057510 | T047;T061 |
34,666,360 | surgeon modifi stent graft complex aortic reconstruct feasibl close anatom relationship viscer vessel render treatment complex throacoabdomin aortic patholog challeng emerg case shelf stent graft parallel techniqu feasibl treatment option altern treat surgeon alter convent stent graft creat call surgeon modifi stent graft smsg adapt complex aortic patholog aim public present possibl result method | D017545;D019917;D057510;D066231 | T097;T047;T061 |
34,666,359 | open thorac thoracoabdomin aortic repair vs fbtevar complementari competit classic approach open repair thorac thoracoabdomin aortic patholog includ aneurysm dissect outnumb use fenestratedbranch thorac endovascular aortic repair fb evar recent year provid complex case aortic servic requir dedic surgic setup huge bodi expertis particular fieldin order reduc specif complic periop mortal kidney failur spinal cord ischemia stroke bowel ischemia necessari appli cerebrospin spinal fluid drainag point care coagul therapi distal retrograd aortic perfus sequenti clamp despit predomin endovascular solut specif expertis still need specif indic young patient connect tissu disord aortic graft infectionscurr short mid term result fb evar outweigh includ shorter hospit stay less invas procedur howev provid better long term result overal mortal intervent rate secondari complicationsin conclus opinion servic still necessari dedic aortic centr like becom frequent year come | D017545;D019917;D057510 | T047;T061 |
34,666,358 | debat infraren aaa young fit patient fit open repair open repair safe long term result better endovascular aortic repair initi develop patient prohibit high risk open repair undergon signific technic evolut refin emerg prefer treatment option patient infraren aortic aneurysm howev analysi long term data randomis studi reveal inferior result regard surviv freedom reintervent eight year open aortic repair perform seven decad especi younger patient comorbid result excel potenti drawback open repair like incision hernia erectil dysfunct qualiti life either effect prevent mesh reinforc actual fail show signific differ compar open repair recent studi therefor meticul assess patient comorbidit use valid paramet key element decis make paramet young age low comorbid profil larg aneurysm presenc atop renal arteri domin inferior mesenter arteri prompt recommend open repair | D017544;D057510 | T047;T061 |
34,666,357 | dilemma seal endovascular aortic aneurysm three way endovascular aneurysm seal eva commerci introduc initi result eva posit lead widespread use mid long term report show greater expect rate migrat led recal devic present articl describ experi manag type ia endoleak migrat occur nellix system three differ way open repair nellix explant nellix nellix applic nina techniqu use multibranch colt devic origin dedic treatment thoracoabdomin aneurysm | D017544;D019917;D057510 | T047;T061 |
34,666,356 | import anatomi train vascular surgeon vascular surgeri develop dynam recent year especi introduct endovascular techniqu howev also chang surgeon requir classic surgic procedur almost complet displac endovascular techniqu new hybrid intervent emerg complex oper concentr centr therefor develop expertis open aortic surgeri increas challeng vascular surgic train programscadav model provid opportun exposur repetit train individu surgic step without endang patientsa part train high complex vascular surgeri oper carri evalu thoracoabdomin aortic replac particip ethanol preserv corpsesa simul surgic procedur human cadaver model fulli replac real experi allow surgeon train practic achiev dexter perform procedur safe reproduc way | D057510;D066231 | T097;T061 |
34,666,352 | defibrotid real world manag veno occlus diseasesinusoid obstruct syndrom stem cell transplant hepat veno occlus diseas sinusoid obstruct syndrom vodso life threaten complic hematopoiet stem cell transplant hsct defibrotid medic approv us food drug administr manag sever vodso hsct report center experi commerci avail defibrotid treatment patient vodso retrospect identifi case vodso base european societi blood marrow transplant criteria march june median day vodso onset day rang day defibrotid initi day diagnosi patient complet resolut vodso occur patient day surviv hsct patient sever vodso respons rate surviv similar patient vodso myeloabl reduc intens chemotherapi hsct therapi relat advers event mild includ hematuria epistaxi hypotens sever hemorrhag advers event occur patient pulmonari hemorrhag upper gastrointestin hemorrhag set progress vodso earli diagnosi prompt initi defibrotid minim dose interrupt may key success treatment vodso | D018380;D006504 | T047;T061 |
34,666,351 | design factor food supplement nutrit educ intervent limit conclus effect wast prevent scope review peer review literatur conduct scope review character evid base effect food supplement fs nutrit educ ne fsne intervent prevent wast among children age mo aim identifi gap peer review literatur develop recommend strengthen studi design identifi uniqu studi fs ne fsne assess intervent design factor implement context evalu method wast impact compar studi focus stunt fewer wast focus studi report weight height z score whz midupp arm circumfer muac common report wast focus studi focus stunt wast stunt fs studi measur anthropometri mean ci frequent everi wk ne intervent wk p fsne intervent wk p ne intervent tend longer durat fs fsne intervent studi follow measur children intervent period end across studi report signific effect wast includ fs ne fsne intervent lack compar across studi limit conclus effect specif type intervent build unifi evid base wast prevent recommend futur studi report consist set metric includ muac attempt measur chang wast incid use frequent measur measur wast preval among general popul follow children postintervent assess relaps measur food insecur diet qualiti use harmon protocol across multipl set effort improv studi compar strengthen evid base may help unit diverg profession communiti ultim acceler progress toward elimin child undernutrit | D015362;D044623 | T058;T047;T061 |
34,666,349 | process tomato product nutriti fresh tomato scope review effect industri process nutrient bioactiv compound tomato tomato second consum veget unit state american peopl consum kg tomato fresh market kg process tomato product per capita one common ask question consum nutrit communiti process tomato product nutriti fresh tomato review address question summar current understand effect industri process nutrient bioactiv compound tomato twelv origin research paper found studi effect differ industri process method nutrient andor bioactiv compound tomato product data suggest differ process method differ effect differ compound tomato howev current avail data still limit exist data often inconsist usda nation nutrient databas standard refer legaci util estim nutrient content raw tomato process tomato product addit sever import factor specif relat industri process tomato also discuss conclud simpl yes answer question process tomato product nutriti fresh tomato mani factor must consid compar nutriti valu fresh tomato process tomato product point suffici data fulli understand factor impact | D018551 | T002;T168 |
34,666,347 | pretherapi metabol tumor volum associ respons cd car cell hodgkin lymphoma group recent demonstr chimer antigen receptor cell therapi target cd antigen cdcar high effect patient relaps refractori rr classic hodgkin lymphoma chl despit high rate clinic respons relaps progress observ subset patient object studi character clinic correl factor associ progress free surviv pfs cdcar cell therapi evalu correl patient rr chl treat lymphodeplet cdcar cell median follow month patient progress median pfs day confid interv reach patient die median overal surviv reach high metabol tumor volum mtv ml immedi lymphodeplet cdcar cell infus associ inferior pfs log rank p persist adjust lymphodeplet car dose log rank p p respect contrast receiv bridg therapi respons bridg therapi cdcar expansionpersist percentag cdpd lymphocyt first week therapi associ differ pfs summari studi report associ high baselin mtv immedi lymphodeplet cdcar cell infus wors pfs patient rr chl trial regist wwwclinicaltrialsgov nct | D006689;D000076962 | T192;T191;T116;T129 |
34,666,344 | sever cytokin releas syndrom associ hematolog toxic follow cd car cell therapi cd target chimer antigen receptor car cell therapi demonstr remark efficaci patient relapsedrefractori b cell malign howev associ toxic includ cytokin releas syndrom crs neurotox impair hematopoiet recoveri latter associ high grade cytopenia requir extend growth factor transfusion support potenti lead addit complic infect hemorrhag date factor independ associ hematolog toxic well character address deficit retrospect analyz patient receiv defin composit cd car cell therapi phase clinic trial https clinicaltrialsgov nct primari end point absolut neutrophil count platelet count day car cell infus observ cumul incid neutrophil platelet recoveri respect day infus hematolog toxic note signific subset patient persist neutropenia thrombocytopenia last follow use debias least absolut shrinkag selector oper regress analysi high dimension model consid patient diseas treatment relat variabl identifi increas crs sever independ predictor decreas platelet count lower prelymphodeplet platelet count independ predictor decreas neutrophil platelet count cd car cell infus furthermor multivari model includ crs relat cytokin identifi associ higher peak serum concentr interleukin lower day cell count contrast higher serum concentr transform growth factor associ higher count find suggest patient select improv crs manag may improv hematopoiet recoveri cd car cell therapi | D016219;D013921 | T047;T061 |
34,666,340 | nasopharyng versus nasal swab detect sar cov systemat review nasopharyng swab nps coupl rt pcr current gold standard detect sar cov infect howev numer studi recent demonstr advantag altern nasal specimen collect approach nps specif covid diagnosi present review conduct accord prisma guidelin summaris current literatur give clear overview nasal specimen collect method sar cov detect public investig nps least one form nasal specimen collect combin rt pcr viral detect context covid assess identifi articl ultim includ studi systemat review suitabl public evalu differ form nasal specimen collect anterior nasal swab an midturbin swab mts frequent examin techniqu analys studi report sensit specif result respect similar achiev via nps especi earli stage diseas pair oropharyng swab result studi suggest an mts suitabl altern nps covid test due eas collect an mts collect techniqu may facilit broader test strategi allow econom medic staff | D000086382;D000086402 | T047;T005;T067 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.